53
Views
4
CrossRef citations to date
0
Altmetric
Letter to the Editor

Alemtuzumab-induced syndrome of inappropriate anti-diuretic hormone

&
Pages 635-637 | Received 24 Nov 2004, Published online: 03 Aug 2009

REFERENCES

  • Keating M, Flinn I, Jain V, Binet J-L, Hillmen P, Byrd J, AlbitarM Brettman L, Santabarbara P, Wacker B, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludaribine: results of a large international study. Blood 2002;99: 3554 —3561.
  • Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, Mollgard L, Rebello P, Hale G, Waldmann H et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768–773.
  • Rai K, Freter C, Mercier R. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who have also received fludaribine. J Chin Oncol 2002;20:3891 —3897.
  • Gutknecht D. Guillain—Barre syndrome and SIADH in a patient with chronic lymphocytic leukemia. J Am Board Fam Pract 1998;11:237 — 239.
  • Hagberg H, Lannemyr 0, Acosta S, Birgegard G. Successful treatment of syndrome of inappropriate antidiuretic secretion (SIADH) in 2 patients with CNS involvement of chronic lymphocytic leukemia. Eur J Haematol 1997;58: 207–208.
  • Ramila E, Martino R, Santamaria A, Sierra J. Inappropriate secretion of antidiuretic hormone as the initial sign of central nervous system progression of nocardiosis in a patient with chronic lymphocytic leukemia. Haematologica 1999;84: 1155–1156.
  • Rye A, Stitson R, Dyer M. Pituitary infiltration in B-cell chronic lymphocytic leukemia. Br J Haematol 2001;115:718.
  • Stagg M, Gumbart C. Chronic lymphocytic leukemic meningi-tis as a cause of the syndrome of inappropriate secretion of antidiuretic hormone. Cancer 1987;60:191 —192.
  • Wagner A, Brunet S, Puig J, Ortega E, Subira M, Puig M. Chlorambucil-induced inappropriate antiduresis in a man with chronic lymphocytic leukemia. Ann Hematol 1999;78:37–38.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.